Impact of Pathological Complete Response in Breast Cancer Following Neoadjuvant Therapy on Patient’s Outcome
Abstract
Background: Patients who achieve a pathological complete response (pCR) after neoadjuvant therapy have better outcomes than patients with residual disease. Despite the excellent prognosis associated with achieving a pCR, recurrence still occurs. The study was conducted with the intent to evaluate factors associated with tumor recurrence and survival among patients achieving pCR after neoadjuvant therapy.
Methods: We evaluated the medical records of patients with breast cancer who received neoadjuvant therapy and achieved pCR in our academic institute. The survival curve was estimated with the Kaplan-Meier method in patients who developed recurrence.
Results: In our retrospective study 2,360 received neoadjuvant therapy out of which 315 (13.3%) who achieved pCR were included in this study. The mean age was 45.85 (range 21-92 years) and the mean duration of follow-up was 41.2 months. The clinical tumor stage T1-T2 represented 55%, T3-T4 was 44.1%, and node-positive was 54%. The primary endpoint was the correlation between pCR achieved after neoadjuvant therapy and disease-free survival or overall survival. . Predictors of pCR were clinical T-stage and receiving appropriate chemotherapy. We observed that patients who had an increased risk of recurrence after achieving pCR were those with clinical stage III-IV, patients with mastectomy, and those with triple-negative tumor subtype.
Conclusion: Achieving pCR after neoadjuvant therapy is distinctly related to the improvement of survival, however patients who achieved a pCR, women younger than 50 years of age and those with stage III/IV disease have a higher risk of developing distant metastasis.
Full text article
References
Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95(1130):20211033. doi:10.1259/bjr.20211033A
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
Khan NH, Duan SF, Wu DD, Ji XY. Better Reporting and Awareness Campaigns Needed for Breast Cancer in Pakistani Women. Cancer Manag Res. 2021 Mar 2; 13:2125-2129. Doi: 10.2147/CMAR.S270671. PMID: 33688255; PMCID: PMC7936924
Shuai Y, Ma L. Prognostic value of pathologic complete response and the alteration of breast cancer immunohistochemical biomarkers after neoadjuvant chemotherapy. Pathol Res Pract. 2019;215(1):29-33. doi: 10.1016/j.prp.2018.11.003
Chaudry M, Lei X, Gonzalez-Angulo AM, et al. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015;153(2):417-423. doi:10.1007/s10549-015-3533-x
Xie LY, Wang K, Chen HL, et al. Markers Associated with Tumor Recurrence in Patients with Breast Cancer Achieving a Pathologic Complete Response After Neoadjuvant Chemotherapy. Front Oncol. 2022; 12:860475. Published 2022 Apr 20. doi:10.3389/fonc.2022.860475
Gonzalez-Angulo AM, McGuire SE, Buchholz TA, et al. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol. 2005;23(28):7098-7104. doi:10.1200/JCO.2005.11.124
Spring LM, Fell G, Arfe A, et al. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020;26(12):2838-2848. doi: 10.1158/1078-0432.CCR-19-3492
Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-1747. doi:10.1093/annonc/mdr304
Gunter von Minckwitz, et al. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. Journal of Clinical Oncology 2012 30:15, 1796-1804
Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022 Dec; 66:15-23. doi: 10.1016/j.breast.2022.08.010. Epub 2022 Sep 2. PMID: 36084384; PMCID: PMC9465273.
Pennisi A, Kieber-Emmons T, Makhoul I, Hutchins L. Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer. Breast Cancer (Auckl). 2016; 10:103-106. Published 2016 Jul 25. doi:10.4137/BCBCR.S33163
Kennedy WR, Tricarico C, Gabani P, et al. Predictors of Distant Metastases in Triple-Negative Breast Cancer Without Pathologic Complete Response After Neoadjuvant Chemotherapy. J Natl Compr Canc Netw. 2020;18(3):288-296. doi:10.6004/jnccn.2019.7366
Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW. Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer. Journal of the National Comprehensive Cancer Network. 2017 Oct 1;15(10):1216-23.
van der Voort A, Liefaard MC, van Ramshorst MS, van Werkhoven E, Sanders J, Wesseling J, Scholten A, Vrancken Peeters MJTFD, de Munck L, Siesling S, Sonke GS. Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival. Breast. 2022 Oct;65:110-115. doi: 10.1016/j.breast.2022.07.005. Epub 2022 Jul 13. PMID: 35921798; PMCID: PMC9356182.
Lv Y, Li Y, Mu W, Fu H. Factors Affecting Pathological Complete Response After Neoadjuvant Chemotherapy in Operable Primary Breast Cancer. J Coll Physicians Surg Pak. 2020;30(4):389-393. doi:10.29271/jcpsp.2020.04.389
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M. Pembrolizumab for early triple-negative breast cancer. New England Journal of Medicine. 2020 Feb 27;382(9):810-21.
Spring L, Greenup R, Niemierko A, et al. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women with Breast Cancer. J Natl Compr Canc Netw. 2017;15(10):1216-1223. doi:10.6004/jnccn.2017.0158
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet. 2014 Jul 12;384(9938):164-72.
Huober J, van Mackelenbergh M, Schneeweiss, A. et al. Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy. npj Breast Cancer 9, 23 (2023). https://doi.org/10.1038/s41523-023-00525-2.
Bardia A, Baselga J. Neoadjuvant therapy as a platform for drug development and approval in breast cancer. Clin Cancer Res. 2013;19(23):6360-6370. doi:10.1158/1078-0432.CCR-13-0916
Selli C, Sims AH. Neoadjuvant Therapy for Breast Cancer as a Model for Translational Research. Breast Cancer (Auckl). 2019; 13:1178223419829072. Published 2019 Feb 19. doi:10.1177/1178223419829072
Authors
Copyright (c) 2023 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.